TNF-blockade in patients with advanced hormone refractory prostate cancer

被引：5
作者：
Diaz, Luis A., Jr. [1 ,2 ]
Messersmith, Wells [3 ]
Sokoll, Lori [2 ,4 ]
Sinibaldi, Vicki [2 ]
Moore, Sandy [2 ]
Carducci, Michael [2 ]
Eisenberger, Mario [2 ]
机构：
[1] Ludwig Ctr Canc Genet & Therapeut Johns Hopkins, Baltimore, MD 21231 USA
[2] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA
[3] Univ Colorado, Div Med Oncol, Ctr Canc, Aurora, CO 80045 USA
[4] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21231 USA
来源：
INVESTIGATIONAL NEW DRUGS | 2011年 / 29卷 / 01期
关键词：
Prostate cancer; Hormone refractory; TNF-alpha; Infliximab; IL-6; INTERLEUKIN-6; PATHWAY; GROWTH;
D O I：
10.1007/s10637-009-9346-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：192 / 194
页数：3
相关论文
共 50 条
  • [21] The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer
    Petrioli, Roberto
    Fiaschi, Anna Ida
    Francini, Edoardo
    Pascucci, Alessandra
    Francini, Guido
    CANCER TREATMENT REVIEWS, 2008, 34 (08) : 710 - 718
  • [22] The need for improved therapeutic strategies for patients with metastatic hormone-refractory prostate cancer
    Anderson, John
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (15) : 811 - 816
  • [23] Combination chemotherapy with weekly docetaxel and estramustine for hormone refractory prostate cancer in Japanese patients
    Takenaka, Atsushi
    Yamada, Yuji
    Kurahashi, Toshifumi
    Soga, Hideo
    Miyake, Hideaki
    Fujisawa, Masato
    INTERNATIONAL JOURNAL OF UROLOGY, 2008, 15 (01) : 106 - 109
  • [24] Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer
    Matsumoto, Akihiro
    Inoue, Atsushi
    Yokoi, Satoshi
    Nozumi, Kazuyoshi
    Miyazaki, Kanetaka
    Hosoki, Shigeru
    Nagata, Maki
    Yamaguchi, Kunio
    INTERNATIONAL JOURNAL OF UROLOGY, 2009, 16 (08) : 687 - 691
  • [25] Radiotherapy for local progression in patients with hormone-refractory prostate cancer
    Furuya, Y
    Akakura, K
    Akimoto, S
    Ichikawa, T
    Ito, H
    INTERNATIONAL JOURNAL OF UROLOGY, 1999, 6 (04) : 187 - 191
  • [26] Therapeutic options for hormone-refractory prostate cancer in 2007
    Hadaschik, Boris A.
    Gleave, Martin E.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2007, 25 (05) : 413 - 419
  • [27] Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer
    Wolff, JM
    ONKOLOGIE, 2003, 26 : 37 - 40
  • [28] Prognostic Role of Serum Parathyroid Hormone Levels in Advanced Prostate Cancer Patients Undergoing Zoledronic Acid Administration
    Berruti, Alfredo
    Cook, Richard
    Saad, Fred
    Buttigliero, Consuelo
    Lipton, Allan
    Tampellini, Marco
    Lee, Ker-Ai
    Coleman, Robert E.
    Smith, Matthew R.
    ONCOLOGIST, 2012, 17 (05) : 645 - 652
  • [29] Maximal androgen blockade for advanced prostate cancer
    Klotz, Laurence
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 22 (02) : 331 - 340
  • [30] Efficacy and toxicity between luteinising hormone releasing hormone analogue therapy and maximal androgen blockade therapy in patients with advanced prostate cancer in China
    Zhang, Cheng
    Wu, Jie
    Zheng, Yuxiao
    Huang, Yuan
    Cheng, Gong
    Hua, Lixin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (06): : 9508 - 9512
12345